Autopsy report · NCT04697758

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

“Adverse Events”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

AsclepiX Therapeutics, Inc.

Sponsor type

Industry

Conditions

Diabetic Macular Edema (DME)

Interventions

AXT107 0.1 mg; AXT107 0.25 mg; AXT107 0.5 mg

Participants

6

Sites

10

Countries

United States

Trials that died the same way

• Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery
  “Adverse Event” (97% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (93% match in meaning)
• Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
  “Due to adverse events” (88% match in meaning)
• Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
  “investigation of adverse events in a related clinical study” (85% match in meaning)
• Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures
  “unexpected serious adverse event” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.